Osivax and GC Biopharma team up on a next-generation flu vaccine, K2 Therapeutics' Ying Huang talks through why so few drugs ...

ACTO CEO Parth Khanna on why sales reps still matter — and how human intelligence plus empathetic agents is the winning formula for field teams.

Pharmaceutical Executive spoke with K2 Therapeutics’ CEO Dr. Ying Huang about the growing shift towards globally sourced innovation and the increased focus on foreign partnerships. The push has become ...

Beyond tau and TREM2: checkpoint inhibition, inflammasome drugs, brain delivery technologies, and biomarker-led diagnostics reshape Alzheimer's pipeline.

The FDA has approved daraxonrasib (brand name Rasonque) for adults with metastatic pancreatic adenocarcinoma who have ...

A new Eli Lilly study links Zepbound to lower healthcare costs in older adults with obesity, Biohaven and Haisco strike major ...

President Donald Trump’s administration is preparing to announce a new round of drug-pricing agreements with midsize biotech ...

Eli Lilly and Company announced results from a real-world study of adults over 55 with obesity or overweight showing that ...

FDA approves Imaavy as the first treatment for warm autoimmune hemolytic anemia, McKesson agrees to acquire Precision ...

Evolving global expectations for CGT validation, comparability, and supply continuity elevate the need for operational and ...

K2 Therapeutics CEO Ying Huang on the drug development pipeline — and the compounding attrition rates that make FDA approval ...

Most Phase 2 trials are sized on a guess seen as mathematics. You are in the trial design meeting, your biostatistician pulls up a standard power calculation, someone picks an effect size that feels ...